Castle Biosciences CSTL 深 沪
已收盘 10-17 16:00:00 美东时间
22.14
-0.390
-1.73%
华盛通- 最 高22.74
- 今 开22.52
- 成交量 23.08万股
- 最 低 22.10
- 昨 收 22.53
- 总市值 6.42亿
- 52周最高 35.84
- 市盈率 静 35.50
- 换手率 0.80%
- 52周最低 14.59
- 委 比 -60.02%
- 总股本 2900.83万
- 历史最高 107.69
- 量 比 0.90
- 振 幅 2.84%
- 历史最低 9.2601
- 每 手 1
- 风险率 5.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
Castle Biosciences, Inc. has been recognized as a Greater Pittsburgh Top Workplace 2025 by The Pittsburgh Post-Gazette, based on anonymous employee feedback. The company ranked third in its size bracket within the healthcare industry and has received eight other workplace accolades this year. Derek Maetzold, CEO, credited the achievement to employees' contributions to improving patient care. Castle Biosciences specializes in innovative diagnostic...
09-23 11:00
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
Castle Biosciences Inc. has been named to Newsweek's inaugural 2025 America's Greatest Companies list, recognizing its strong performance in financial strength, workforce dedication, innovation, and environmental sustainability. The company, which specializes in innovative diagnostic tests to improve patient care, was praised for its commitment to putting people first in all aspects of its business.
09-17 11:00
Castle Biosciences Study Finds 15% of Barrett's Esophagus Patients Face Higher Cancer Risk Than Pathology Suggests
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized risk stratification provided by its
09-09 19:19
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
<p>TissueCypher的最新研究显示，15%的非发育不良性Barrett食管(NDBE)患者疾病进展风险与低级别发育不良(LGD)相似或更高，而现行指南建议对LGD患者进行及时干预以防止疾病进展。这项研究将在2025年美国腑 GCC 会上以主题演讲形式分享。研究结果表明，TissueCypher能够提供比传统病理更精准的风险评估，识别出易被忽视的高风险患者，从而帮助医生制定个性化随访和治疗策略，降低患者发展为食管腺癌的风险。</p>
09-09 11:00
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
Two new studies highlight DecisionDx-SCC's superior performance in predicting local recurrence and metastasis risks for high-risk cutaneous squamous cell carcinoma (SCC) patients, surpassing current staging systems. The test also aligns with clinician treatment thresholds for adjuvant radiation therapy and surveillance imaging. Among 414 high-risk SCC patients, DecisionDx-SCC significantly stratified risk, showing progressively lower survival rat...
08-25 11:00
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that its executive management will present a company overview at Baird’s 2025 Global Healthcare Conference on September 10, 2025, at 10:15 a.m. Eastern time. The presentation will be available via live audio webcast on the company’s website and replay afterward. Additionally, the company will host one-on-one investor meetings at the Wells Fargo 20th Annual Healthcare Conference on September 4, 202...
08-21 11:00
Castle Biosciences Updates Bylaws for Improved Governance
The latest update is out from Castle Biosciences ( ($CSTL) ). On August 5, 2025...
08-09 04:41
A Preview Of Performant Healthcare's Earnings
Performant Healthcare (NASDAQ:PHLT) is gearing up to announce its quarterly ear...
08-07 03:03
美股牛股 | 创新药企YMAB单日翻倍！华米科技再升38%，近一个月涨幅超770%
创新药企YMAB单日翻倍！获SERB制药宣布全现金收购；华米科技隔夜再升38%，Q2业绩显著提升，近一个月累涨超770%>>
08-06 17:04
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Y-mAbs Therapeutics (NASDAQ:YMAB) stock rose 103.2% to $8.52 during Tu...
08-06 01:06
